PMID- 34076265
OWN - NLM
STAT- MEDLINE
DCOM- 20210921
LR  - 20210921
IS  - 1097-4598 (Electronic)
IS  - 0148-639X (Linking)
VI  - 64
IP  - 3
DP  - 2021 Sep
TI  - Impact of subcutaneous immunoglobulin on quality of life in patients with chronic 
      inflammatory demyelinating polyneuropathy previously treated with intravenous 
      immunoglobulin.
PG  - 351-357
LID - 10.1002/mus.27345 [doi]
AB  - INTRODUCTION/AIMS: Intravenous immunoglobulin (IVIg) is a common therapy for 
      patients with chronic inflammatory demyelinating polyneuropathy (CIDP). IVIg may 
      cause systemic adverse events (AEs); therefore, infusion of subcutaneous 
      immunoglobulin (SCIg) may be preferred by some patients. In this study we 
      document the experiences of patients transitioning from IVIg to SCIg. METHODS: 
      Transitioning subjects with CIDP were followed in a 6-month prospective, 
      open-label study. The primary endpoint was percentage of subjects who withdrew 
      for any reason (including significant AEs). The secondary endpoint was symptom 
      progression or relapse requiring a change in management. Quality of life (QOL) 
      and treatment satisfaction were assessed using the Short Form 36-item Health 
      Survey (SF-36), Treatment Satisfaction Questionnaire for Medication (TSQM), and 
      Chronic Acquired Polyneuropathy Patient-Reported Index (CAP-PRI). Efficacy was 
      assessed using the Inflammatory Rasch-built Overall Disability Scale, hand-held 
      dynamometry, limb motor strength testing (LMST), and timed 25-ft walk (T25-FW). 
      RESULTS: Fifteen CIDP subjects transitioned from IVIg to SCIg. Of these, three 
      (20%) met the primary endpoint and one (7%) met the secondary endpoint. The SF-36 
      showed a statistically significant improvement for the domain of role 
      limitations-physical after 24 weeks (P = .03), with no significant differences 
      observed in other domains. TSQM and CAP-PRI showed significant differences in 
      favor of SCIg (P = .003 and .02, respectively). No significant differences were 
      observed in efficacy after 24 weeks, except for LMST, which favored SCIg 
      (P = .003). Eight of the 12 study completers (67%) continued with SCIg. 
      DISCUSSION: Transition to SCIg was associated with maintained efficacy and 
      improved QOL.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Vu, Tuan
AU  - Vu T
AUID- ORCID: 0000-0003-0724-0210
AD  - GBS/CIDP Center of Excellence, University of South Florida, Tampa, Florida, USA.
FAU - Anthony, Natalie
AU  - Anthony N
AD  - GBS/CIDP Center of Excellence, University of South Florida, Tampa, Florida, USA.
FAU - Alsina, Raul
AU  - Alsina R
AD  - GBS/CIDP Center of Excellence, University of South Florida, Tampa, Florida, USA.
FAU - Harvey, Brittany
AU  - Harvey B
AD  - GBS/CIDP Center of Excellence, University of South Florida, Tampa, Florida, USA.
FAU - Schleutker, Allison
AU  - Schleutker A
AD  - GBS/CIDP Center of Excellence, University of South Florida, Tampa, Florida, USA.
FAU - Farias, Jerrica
AU  - Farias J
AD  - GBS/CIDP Center of Excellence, University of South Florida, Tampa, Florida, USA.
FAU - Dang, Samuel
AU  - Dang S
AD  - GBS/CIDP Center of Excellence, University of South Florida, Tampa, Florida, USA.
FAU - Suresh, Niraja
AU  - Suresh N
AD  - GBS/CIDP Center of Excellence, University of South Florida, Tampa, Florida, USA.
FAU - Gooch, Clifton
AU  - Gooch C
AD  - GBS/CIDP Center of Excellence, University of South Florida, Tampa, Florida, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210615
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/administration & dosage/*therapeutic use
MH  - Immunoglobulins, Intravenous/administration & dosage/*therapeutic use
MH  - Infusions, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/*drug therapy
MH  - Quality of Life/*psychology
MH  - Retreatment
MH  - Treatment Outcome
OTO - NOTNLM
OT  - CIDP
OT  - QOL
OT  - SCIg
OT  - immunoglobulin
OT  - patient-reported outcomes
OT  - treatment
EDAT- 2021/06/03 06:00
MHDA- 2021/09/22 06:00
CRDT- 2021/06/02 09:20
PHST- 2021/05/26 00:00 [revised]
PHST- 2020/07/14 00:00 [received]
PHST- 2021/05/28 00:00 [accepted]
PHST- 2021/06/03 06:00 [pubmed]
PHST- 2021/09/22 06:00 [medline]
PHST- 2021/06/02 09:20 [entrez]
AID - 10.1002/mus.27345 [doi]
PST - ppublish
SO  - Muscle Nerve. 2021 Sep;64(3):351-357. doi: 10.1002/mus.27345. Epub 2021 Jun 15.